Skip to main content
SpringerLink
Log in

Evaluation of Quality of Life in Cancer Clinical Trials

  • Chapter
Current Cancer Therapeutics

  • 129 Accesses

Abstract

Quality of life is an important consideration when making treatment decisions [1–3]. The choice of one treatment option over another for an individual patient may hinge on how the treatments affect quality of life. Therefore, it is important that the practicing oncologist has a thorough understanding of the potential impacts that treatments can have on quality of life in general as well as an understanding of the individual patient’s needs and preferences. To help address these issues, the evaluation of quality of life is taking on an increasingly larger role in cancer clinical research. In particular, patient-oriented quality-of-life assessments are frequently being included in clinical trials as study endpoints for treatment comparisons. The purpose of this chapter is to provide an overview of the most common methods used in cancer clinical trials for the evaluation of quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Schumacher M, Olschewski M, Schulgen G: Assessment of quality of life in clinical trials. Stat Med 1991,10:1915–1930.

    Article  PubMed  CAS  Google Scholar 

  2. Cox DR, Fitzpatrick R, Fletcher AE, et al.: Quality of life assessment: can we keep it simple? JR Stat SocA 1992; 155:353–393.

    Article  Google Scholar 

  3. Gelber RD, Goldhirsch A, Hürny C, et al.: Quality of life in clinical trials of adjuvant therapies. JNatl Cancer Inst Monogr 1992, 11:127–135.

    Google Scholar 

  4. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH: The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948, 1:634.

    Article  Google Scholar 

  5. Yates JW, Chalmer B, McKegney FP: Evaluation of patients with advanced cancer using the Karnofsky Performance Status. Cancer 1980, 45:2220–2224.

    Article  PubMed  CAS  Google Scholar 

  6. Zubrod CG, Schneiderman M, Frei E, et al.: Appraisal of methods for the study of chemotherapy in man. J Chron Dis 1960, 11:7.

    Article  Google Scholar 

  7. Izsak FC, Medalie JH: Comprehensive follow-up of carcinoma patients. J Chron Dis 1971, 24:179–191.

    Article  PubMed  CAS  Google Scholar 

  8. Burge PS, Prankerd TA, Richards JD, et al.: Quality and quantity of survival in acute myeloid leukemia. Lancet 1975, 2:621–624.

    Article  PubMed  CAS  Google Scholar 

  9. Priestman TJ, Baum M: Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1976, 1:899–900.

    Article  PubMed  CAS  Google Scholar 

  10. Ware JE Jr: The SF-36 health survey. In Quality of Lift and Pharmacoeconomics in Clinical Trials,edn 2. Edited by Spilker B. Philadelphia: Lippincott-Raven Publishers; 1996:337–345.

    Google Scholar 

  11. Damiano ANI: The sickness impact profile. In Quality of Lift and Pharmacoeconomics in Clinical Trials,edn 2. Edited by Spilker B. Philadelphia: Lippincott-Raven Publishers; 1996:347–354.

    Google Scholar 

  12. Derogatis LR, Derogatis MF: SCL-90-R and the BSI. In Quality of Life and Pharmacoeconomics in Clinical Trials, edn 2. Edited by Spilker B. Philadelphia: Lippincott-Raven Publishers; 1996:323–335.

    Google Scholar 

  13. Szabo S: The World Health Organization quality of life (WHOQOL) assessment instrument. In Quality of Life and Pharmacoeconomics in Clinical Trials, edn 2. Edited by Spilker B. Philadelphia: Lippincott-Raven Publishers; 1996:355–362.

    Google Scholar 

  14. Levine MN, Guyatt GH, Gent M: Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Onco1 1988, 6:1789–1810.

    Google Scholar 

  15. Ganz PA, Schag CAC, Lee JJ, et al.: The CARES: a generic measure of health-related quality of life for patients with cancer. Qual Life Res 1992, 1:19–29.

    Article  PubMed  CAS  Google Scholar 

  16. Aaronson NK, Bullinger M, Ahmedzai S: A modular approach to quality-of-life assessment in cancer clinical trials. Recent Results Cancer Res 1988, 111:231–249.

    Article  PubMed  CAS  Google Scholar 

  17. Cella DF, Bonomi AE: The functional assessment of cancer therapy (FACT) and functional assessment of HIV infection (FAHI) quality of life measurement system. In Quality of Life and Pharmacoeconomics in Clinical Trials,edn 2. Edited by Spilker B. Philadelphia: Lippincott-Raven Publishers; 1996:203–214.

    Google Scholar 

  18. Clinch JJ: The functional living index-cancer: ten years later. In Quality of Lift and Pharmacoeconomics in Clinical Trials,edn 2. Edited by Spilker B. Philadelphia: Lippincott-Raven Publishers; 1996:215–225.

    Google Scholar 

  19. Hürny C, Bernhard J, Gelber RD, et al.: Quality of life measures for patients receiving adjuvant therapy for breast cancer. Eur J Cancer 1992, 28:118–124.

    Article  PubMed  Google Scholar 

  20. Spitzer WO, Dobson AJ, Hall J, et al.: Measuring the quality of life of cancer patients. J Chron Dis 1981, 34:585–597.

    Article  PubMed  CAS  Google Scholar 

  21. Bennett KJ, Torrance GW: Measuring health state preferences and utilities: rating scale, time trade-off and standard gamble techniques. In Quality of Lift and Pharmacoeconomics in Clinical Trials,edn 2. Edited by Spilker B. Philadelphia: Lippincott-Raven Publishers; 1996:253–265.

    Google Scholar 

  22. Kind P: The EuroQoL instrument: an index of health-related quality of life. In Quality of Life and Pharmacoeconomics in Clinical Trials,edn 2. Edited by Spilker B. Philadelphia: Lippincott-Raven Publishers; 1996:191–201.

    Google Scholar 

  23. Feeny DH, Torrance GW, Furlong WJ: Health utilities index. In Quality of Lift and Pharmacoeconomics in Clinical Trials,edn 2. Edited by Spilker B. Philadelphia: Lippincott-Raven Publishers; 1996:239–252.

    Google Scholar 

  24. Weeks J, O’Leary J, Fairclough D, et al. The `Qtility index’: a new tool for assessing health-related quality of life and utilities in clinical trials and clinical practice. ProcAm Soc Clin Oncol 1994, 13:436.

    Google Scholar 

  25. Proceedings of the Workshop on Missing Data in Quality of Life Research in Cancer Clinical Trials: practical and methodological issues: July 1–3, 1996, Bad Horn, Switzerland. Stat Med 1998, 17:511–796.

    Google Scholar 

  26. Gelber RD, Cole BF, Gelber S, Goldhirsch A: The Q-TWiST method. In Quality of Life and Pharmacoeconomics in Clinical Trials,edn 2. Edited by Spilker B. Philadelphia: Lippincott-Raven Publishers; 1996:437–444.

    Google Scholar 

  27. Kirkwood JM, Hunt Strawderman M, Ernstoff MS, et al.: Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST1684. J Clin Oncol 1996, 14:7–17.

    PubMed  CAS  Google Scholar 

  28. Cole BF, Gelber RD, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group Study. J Clin Onco11996, 14:2666–2673.

    Google Scholar 

  29. Spilker B (ed): Quality of Life and Pharmacoeconomics in Clinical Trials,edn 2. Philadelphia: Lippincott-Raven Publishers; 1996.

    Google Scholar 

  30. Gelber R, Gelber S: Quality-of-life assessment in clinical trials. In Recent Advances in Clinccal Trial Design and Analysis. Edited by Thall PF. Norwell, MA: Kluwer Academic Publishers; 1995.

    Google Scholar 

  31. Kilbridge KL, Cole BF, Kirkwood JM, et al.: Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2b (HDI) for high-risk melanoma patients (pts) based on E1690 and E1684 (abstract). Proc ASCO 2000, 19:570a.

    Google Scholar 

Download references

Authors
  1. Bernard F. Cole
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard D. Gelber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shari Gelber
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Cole, B.F., Gelber, R.D., Gelber, S. (2001). Evaluation of Quality of Life in Cancer Clinical Trials. In: Current Cancer Therapeutics. Current Medicine Group, London. https://doi.org/10.1007/978-1-4613-1099-0_30

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1099-0_30

  • Publisher Name: Current Medicine Group, London

  • Print ISBN: 978-1-57340-176-0

  • Online ISBN: 978-1-4613-1099-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation